Is giritinib/segatan safe for the elderly?

Elderly patients with acute myeloid leukemia(AML) are often accompanied by underlying diseases and decreased organ function, and have poor tolerance to traditional chemotherapy. Therefore, the application of targeted drugs such as Gilteritinib has received great attention. As an oral FLT3 inhibitor, giritinib has the characteristics of strong targeting and relatively controllable toxicity compared with traditional chemotherapy, providing a safer treatment option for elderly patients.

Overseas clinical practice shows that giritinib can still improve hematological indicators, including platelet and neutrophil levels, while reducing chemotherapy-related serious adverse events in elderly patients. When using giritinib in elderly patients, individualized dosage evaluation should be conducted and adjusted based on liver and kidney function, previous medication history, and potential drug interactions. Giritinib is well absorbed orally, and its metabolism mainly relies on the liver's CYP3A4 enzyme system. Therefore, in the elderly with reduced liver function or combined with other drugs, liver function and blood drug concentration should be closely monitored to prevent adverse reactions.

The oral administration of giritinib reduces the dependence on intravenous infusion and the number of hospitalizations, and improves the quality of life of elderly patients. Overseas guidelines recommend that elderly patients should have regular blood routine and liver and kidney function monitoring during treatment in order to detect cytopenias or other potential toxicities early. Some patients may experience mild to moderate fatigue, headache, or fluctuations in liver function indicators, but it is generally well tolerated. Individualized management under the guidance of a doctor can maximize the efficacy while ensuring medication safety.

In general, giritinib has a high safety profile in elderly patientsAML, but it is still necessary to strictly follow the monitoring plan and individualized dose management to ensure efficacy while reducing medication risks, and to provide sustainable targeted therapy options for elderly patients.

Reference materials:https://www.xospata.com/